4D Molecular Therapeutics Inc (NASDAQ:FDMT)’s traded shares stood at 1.42 million during the last session, with the company’s beta value hitting 2.77. At the close of trading, the stock’s price was $8.83, to imply an increase of 10.10% or $0.81 in intraday trading. The FDMT share’s 52-week high remains $36.25, putting it -310.53% down since that peak but still an impressive 17.1% since price per share fell to its 52-week low of $7.32. The company has a valuation of $408.19M, with an average of 0.77 million shares in intraday trading volume over the past 10 days and average of 802.33K shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for 4D Molecular Therapeutics Inc (FDMT), translating to a mean rating of 1.30. Of 4 analyst(s) looking at the stock, 0 analyst(s) give FDMT a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 4 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -0.84.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
4D Molecular Therapeutics Inc (NASDAQ:FDMT) trade information
After registering a 10.10% upside in the last session, 4D Molecular Therapeutics Inc (FDMT) has traded red over the past five days. The 5-day price performance for the stock is 8.74%, and 4.50% over 30 days. With these gigs, the year-to-date price performance is -56.42%. Short interest in 4D Molecular Therapeutics Inc (NASDAQ:FDMT) saw shorts transact 8.18 million shares and set a 9.89 days time to cover.
The extremes give us $30 and $58 for target low and target high price respectively. As such, FDMT has been trading -556.85% off suggested target high and -239.75% from its likely low.
4D Molecular Therapeutics Inc (FDMT) estimates and forecasts
Looking at statistics comparing 4D Molecular Therapeutics Inc share performance against respective industry, we note that the company has underperformed competitors. 4D Molecular Therapeutics Inc (FDMT) shares are -65.15% down over the last 6 months, with its year-to-date growth rate lower than industry average at -6.20% against 16.20%. Revenue is forecast to shrink -9.22% this quarter before falling -31.82% for the next one. The rating firms project that company’s revenue will shrink -92.05% compared to the previous financial year.
Revenue forecast for the current quarter as set by 4 analysts is 1.93M. Meanwhile, for the current quarter, a total of 3 analyst(s) estimate revenue growth to 176k.Earnings reports from the last fiscal year show that sales brought in -19k and 28k respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to rise 10,231.58% before jumping 528.57% in the following quarter.
FDMT Dividends
4D Molecular Therapeutics Inc has its next earnings report out on 2024-Nov-13. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
4D Molecular Therapeutics Inc (NASDAQ:FDMT)’s Major holders
4D Molecular Therapeutics Inc insiders hold 3.91% of total outstanding shares, with institutional holders owning 127.04% of the shares at 132.22% float percentage. In total, 127.04% institutions holds shares in the company, led by RA CAPITAL MANAGEMENT, L.P.. As of 2024-06-30, the company held over 5.1 million shares (or 10.3471% of shares), all amounting to roughly $107.01 million.
The next major institution holding the largest number of shares is BLACKROCK INC. with 4.9 million shares, or about 9.9385% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $102.79 million.
